Does Dr. MICHAEL AMMAR have financial conflicts of interest?

Dr. MICHAEL AMMAR (MD) has received a total of $76,521 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $76,521 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MICHAEL AMMAR?

According to CMS Open Payments data, Dr. MICHAEL AMMAR received funding from REGENERON HEALTHCARE SOLUTIONS ($51,781), GENENTECH USA ($10,158), and REGENERON PHARMACEUTICALS ($8,509).

Does Dr. MICHAEL AMMAR receive research grants or speaking fees?

Dr. MICHAEL AMMAR has received $76,521 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MICHAEL AMMAR

MDReal-Time Hydrated

Specialty: Ophthalmology, Retina Specialist

Practice Location: POWAY, CA 92064

NPI Number: 1982099115

LIFETIME INDUSTRY VALUE

$76,521

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. AMMAR is a verified Ophthalmology, Retina Specialist practitioner based in POWAY, CA.

Between 2021 and 2025, Dr. AMMAR had an overall industry promotional and research financial footprint of $76,521 as recorded in the federal CMS Open Payments database.

$76,521 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. AMMAR's primary funding source is REGENERON HEALTHCARE SOLUTIONS, which accounts for $51,781 (representing 67.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

REGENERON HEALTHCARE SOLUTIONS

Rank 1

$51,781

67.7%

GENENTECH USA

Rank 2

$10,158

13.3%

REGENERON PHARMACEUTICALS

Rank 3

$8,509

11.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.